French Translation and Validation of the PEYronie's Disease QUESTionnaire

This study is a prospective cohort dedicated to peyronie's disease. The aim is to validate the french translation of the peyronie's disease questionnaire. The primary endpoint is the response rate to the questionnaire.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Peyronie Disease Connective Tissue Diseases Genital Diseases Genital Diseases, Male Male Urogenital Diseases Penile Diseases Penile Induration Skin and Connective Tissue Diseases Urogenital Diseases

Age range

18 year and older

Sex eligibility

Male

Study type

Observational

Primary location

Toulouse Hospital

Toulouse, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Adult patient with Peyronie's Disease clinically diagnosed during a consultation, with palpation of at least one plaque

Exclusion criteria

Patient refusing to participate
Patient with difficulties in understanding the French language.
Protected persons referred to in articles L.1121-6 to L.1121-8 of the public health code

Treatment and study plan

FRAnçaise du PEYronie's Disease QUESTionnaire

Other

Complete an online FRAnçaise du PEYronie's Disease QUESTionnaire

Primary outcomes

Rate of responses

Time frame: Day 0

Response rate to the online questionnaire.

Sponsors and collaborators

Lead sponsor

University Hospital, Toulouse

Other

Registry information

Acronym: FRAPEYQUEST

Important dates

Study start: 2023
Primary completion: 2023
Study completion: 2023
First posted: Mar 14, 2023
Registry last updated: Aug 27, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed